Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 4 Cholangiocarcinoma 3 Neoplasms 2 Adenocarcinoma Of Esophagus 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Advanced and Metastatic Urothelial Cancer 1

Interventions

Gemcitabine 32 Cisplatin 31 durvalumab 15 pembrolizumab 14 Fluorouracil 13 Oxaliplatin 12 Leucovorin 12 Capecitabine 10 Bevacizumab 8 lenvatinib 7 Nivolumab 7 zanidatamab 4 Trastuzumab 4 S 1 (combination) 4 Paclitaxel 4 Liquid Biopsy 4 Irinotecan 4 Carboplatin 4 Albumin-Bound Paclitaxel 4 tremelimumab 3 tislelizumab 3 irinotecan sucrosofate 3 Injections 3 Folfox protocol 3 130-nm albumin-bound paclitaxel 3 toripalimab 2 pertuzumab 2 niraparib 2 ivosidenib 2 envafolimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × futibatinib × 1 year × Clear all

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡